Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05888831 · ClinicalTrials.gov registry record · Phase 1

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 1
Development phase
100
Enrollment target
20
Study locations

NCT05888831 is a Phase 1 study of Advanced Solid Tumors that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 100 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05888831, a Phase 1 study of Advanced Solid Tumors, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety and efficacy of BMS-986449 alone and in combination with nivolumab in participants with advanced solid tumors.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG Nivolumab
  • DRUG BMS-986449

Study Locations (20)

Other

  • Local Institution - 0003 - Bordeaux
  • Local Institution - 0026 - Bergamo
  • Local Institution - 0025 - Roma
  • Local Institution - 0018 - Groningen
  • Local Institution - 0014 - Madrid
  • Local Institution - 0011 - Madrid

California

  • Local Institution - 0021 - Los Angeles

Connecticut

  • Local Institution - 0007 - New Haven

New Jersey

  • Local Institution - 0010 - Hackensack

New York

  • Local Institution - 0022 - Lake Success

Bruxelles-Capitale, Région de

  • Local Institution - 0016 - Brussels

Oost-Vlaanderen

  • Local Institution - 0017 - Ghent

Paris

  • Local Institution - 0002 - Villejuif

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2023-06-06
Est. Completion 2026-09-30
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05888831

The ClinicalTrials.gov registry entry for NCT05888831 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (49% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.

NCT05888831 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT05888831 about?

NCT05888831 is a clinical study titled "A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors". The purpose of this study is to evaluate the safety and efficacy of BMS-986449 alone and in combination with nivolumab in participants with advanced solid tumors.

What is the current status of trial NCT05888831?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2023-06-06. Estimated completion is 2026-09-30.

What conditions does trial NCT05888831 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT05888831?

The interventions under investigation include: Nivolumab (DRUG), BMS-986449 (DRUG).

Who is sponsoring clinical trial NCT05888831?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05888831 being conducted?

This trial has 20 study locations across California, Connecticut, New Jersey, New York, Bruxelles-Capitale, Région de. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.